DxLab Inc.

DxLab Inc. is a medical device and biotechnology company that has developed a portable, point-of-care molecular testing system known as the DxHub. This platform utilizes proprietary isothermal amplification technology to perform rapid infectious disease diagnostics directly from crude specimens, eliminating the need for complex sample purification or central laboratory processing. The DxHub system features a unique design with eight independently controlled reaction chambers, allowing for high-throughput, random-access testing that can return lab-grade results in as little as 10 to 25 minutes. The company's technology is designed as an open platform capable of running a variety of assays, ranging from their own multiplex tests to those developed by third parties, providing flexibility to adapt to evolving pathogen detection needs.

This technology is primarily aimed at healthcare providers, clinics, and public health responders who require accurate, actionable diagnostic data in real-time. By enabling on-site testing in diverse environments, from hospitals to field-based surveillance settings, the system aims to improve patient care outcomes and outbreak response times. DxLab has demonstrated the viability of its platform through FDA Emergency Use Authorization for its COVID-19 testing solution and has secured strategic partnerships, including a multi-million dollar contract with the U.S. Air Force via AFWERX, to adapt its technology for mission-critical respiratory infectious disease detection. Founded in 2020 and based in Somerville, Massachusetts, the firm continues to expand its product pipeline to address various high-priority infectious diseases.